Download PDFPDF
Patent ductus arteriosus: lack of evidence for common treatments
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

  • Published on:
    Conservative treatment of symptomatic patent ductus arteriosus beyond the first week of life
    • Jasper V Been, Paediatric Resident
    • Other Contributors:
      • Boris W. Kramer, Twan L.M. Mulder, Luc J.I. Zimmermann

    Bose and Laughon have clearly reviewed the lack of evidence for current treatments of patent ductus arteriosus (PDA) in preterm infants.[1] As highlighted, the general tendency to treat a clinically relevant PDA for fear of adverse clinical outcome with either indomethacin or surgery when indomethacin fails has caused a lack of information on the natural history of symptomatic PDA. Spontaneous PDA closure has been report...

    Show More
    Conflict of Interest:
    None declared.